Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.

By S. Bansal, J. Buring, N. Rifai, S. Mora, F. Sacks, P. Ridker. Journal of the American Medical Association (JAMA), 2007

1,669 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/a4022bac1cbc833663bc50456fefcec97a09b36b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. Børge G. Nordestgaard
3. S. Grundy
4. G. Moneta
5. Jan Boren
6. M. Chapman
7. R. Eckel
8. P. Poirier

In Epidemiology

1. Børge G. Nordestgaard
2. S. Grundy
3. R. Eckel
4. G. Moneta
5. I. Graham
6. Deborah Lawlor
7. N. Rifai
8. P. Zimmet

In Physiology

1. Børge G. Nordestgaard
2. I. Graham
3. S. Grundy
4. R. Eckel
5. P. Poirier
6. Yun Li
7. P. Zimmet

Citations in the corpus

• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “Based on the available evidence, apo B appears to be a risk factor at least as good as LDL-C and a better index of the adequacy of LDL-lowering therapy than LDL-C.46 Also, there now appears to be less laboratory error in the determination of apo B than of LDL-C, particularly in patients with HTG.”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “PUFAs of the n-3 series have no hypocholesterolaemic effect; conversely, when they are used at high dosages (>3 g/day), the effect on LDL-C levels is either neutral or a slight increase [particularly with docosahexaenoic acid (DHA)] with a concomitant decrease of TGs. 165 A positive relationship exi”
• Guidelines for the Primary Prevention of Stroke (2011, neutral): “but not fasting triglycerides, were associated with cardiovascular events, including ischemic stroke.(151) A meta-analysis of”
• 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. (2016, background): “Although nonfasting triglycerides are predictive of increased CVD and mortality risk, and increased levels are indicators of insulin resistance and atherogenic remnant lipoproteins, 34,35 nonfasting triglyceride targets are not currently included in any national lipid guidelines.”
• Major Lipids, Apolipoproteins, and Risk of Vascular Disease (2009, neutral): “Finally, in contrast with previous findings based on much less data, triglyceride concentration was not independently related with CHD risk after controlling for HDL-C, non–HDL-C, and other standard risk factors, including null findings in women and under nonfasting conditions.(21,22)”
• Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. (2016, positive): “Interestingly, in the Women’s Health Study, elevated triglycerides were associated with high risk of IHD in the nonfasting state, but not in the fasting state.(52)”